Addiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.
Department of Experimental and Health Sciences (CEXS), Universitat Pompeu Fabra, 08002, Barcelona, Spain.
Trials. 2022 Jun 22;23(1):524. doi: 10.1186/s13063-022-06399-2.
Cannabis is the most-frequently used illicit drug in Europe. Over the last few years in Spain, treatment demand has increased, yet most cannabis users do not seek treatment despite the related problems. A web-based self-help tool, like CANreduce 2.0, could help these users to control their consumption.
This study protocol describes a three-arm randomized controlled trial (RCT) comparing the effectiveness of three approaches, in terms of reducing cannabis use among problematic cannabis users, the first two treatment arms including the Spanish version of CANreduce 2.0 (an adherence-focused, guidance-enhanced, web-based self-help tool) (1) with and (2) without psychological support; and the third group (3) treatment as usual (TAU). Study hypotheses will be tested concerning the primary outcome: change in the number of days of cannabis use over the previous week, comparing assessments at 6 weeks and 3 and 6 months follow-up between groups and against baseline. Secondary outcomes related to cannabis use will be tested similarly. Mental disorders will be explored as predictors of adherence and outcomes. Analyses will be performed on an intention-to-treat basis, then verified by complete case analyses.
This study will test how effective the Spanish version of CANreduce 2.0 (CANreduce-SP) is at reducing both the frequency and quantity of cannabis use in problematic users and whether adding psychological support increases its effectiveness.
This trial is registered with the Clinical Trials Protocol Registration and Results System (PRS) number: NCT04517474 . Registered 18 August 2020, (Archived by archive.is https://archive.is/N1Y64 ). The project commenced in November 2020 and recruitment is anticipated to end by November 2022.
大麻是欧洲使用最频繁的非法药物。在过去的几年里,西班牙的治疗需求有所增加,但大多数大麻使用者尽管存在相关问题,但仍未寻求治疗。基于网络的自助工具,如 CANreduce 2.0,可以帮助这些用户控制他们的消费。
本研究方案描述了一项三臂随机对照试验(RCT),比较了三种方法在减少问题性大麻使用者大麻使用量方面的有效性,前两种治疗方法包括西班牙版 CANreduce 2.0(一种以依从性为重点、增强指导的基于网络的自助工具)(1)和(2),同时提供和不提供心理支持;第三组(3)为常规治疗(TAU)。研究假设将针对主要结果进行检验:比较各组之间和与基线相比,6 周和 3 个月及 6 个月随访时,过去一周大麻使用天数的变化。类似地,将对与大麻使用相关的次要结果进行测试。精神障碍将作为依从性和结果的预测因素进行探索。分析将基于意向治疗进行,然后通过完整病例分析进行验证。
本研究将测试西班牙版 CANreduce 2.0(CANreduce-SP)在减少问题性使用者大麻使用频率和数量方面的有效性,以及是否增加心理支持会提高其效果。
本试验在临床试验方案注册和结果系统(PRS)中注册,注册号为:NCT04517474。于 2020 年 8 月 18 日注册(由 archive.is/archiveit.org 存档)。该项目于 2020 年 11 月开始,预计招募将于 2022 年 11 月结束。